Why 2/5: Establishes a work group for a report due in over two years, with no immediate operational changes.
Virginia will establish a work group to evaluate the federal 340B Drug Pricing Program's effects on drug pricing, governance, and pharmacy access in the Commonwealth. This group will specifically examine the program's impacts on transparency and the availability of pharmacy services in rural and underserved areas, reporting its findings by November 1, 2026.
Cleared committee
Reported from Health and Human Services with amendment(s) (21-Y 0-N)
Second reading
Read second time
Third reading
Read third time
Amendment adopted
committee amendments agreed to
Update
Engrossed by House as amended
Passed a chamber
Passed House with amendments (97-Y 0-N 0-A)
Amendment adopted
House amendments agreed to by Senate (39-Y 0-N 0-A)
Enrolled
Enrolled
Passed a chamber
Bill text as passed Senate and House (SB278ER)
This bill has passed its votes and is headed to the Governor's desk. You still have a say — the Governor's office reads messages before deciding whether to sign.
New to all this? See how a bill becomes law →
Summarized from the official bill text (“Federal 340-B Drug Pricing Program; impacts within the Commonwealth.”) · Read the actual bill →
Update
Fiscal Impact Statement from Department of Planning and Budget (SB278)
Passed a chamber
Signed by President
Passed a chamber
Signed by Speaker
Enrolled
Enrolled Bill communicated to Governor on March 14, 2026
Sent to the Governor
Governor's Action Deadline 11:59 p.m., April 13, 2026
Signed into law
Approved by Governor-Chapter 887 (effective 7/1/2026)